John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 60,218 shares at $296.07 ($18.3M) on 2026-07-10, disclosed to the SEC on 2026-07-14.
Scheduled sale ($18.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $296.07 | 1,493 | $442K | 2.4% |
| 2 | $297.23 | 1,314 | $391K | 2.1% |
| 3 | $298.35 | 3,074 | $917K | 5.0% |
| 4 | $298.94 | 5,143 | $1.5M | 8.4% |
| 5 | $300.12 | 370 | $111K | 0.6% |
| 6 | $301.18 | 150 |
| $45K |
| 0.2% |
| 7 | $302.19 | 136 | $41K | 0.2% |
| 8 | $303.03 | 18 | $5K | 0.0% |
| 9 | $301.94 | 798 | $241K | 1.3% |
| 10 | $302.79 | 4,584 | $1.4M | 7.6% |
| 11 | $303.83 | 26,294 | $8.0M | 43.8% |
| 12 | $304.68 | 8,438 | $2.6M | 14.1% |
| 13 | $305.57 | 846 | $259K | 1.4% |
| 14 | $306.82 | 7,240 | $2.2M | 12.2% |
| 15 | $307.40 | 320 | $98K | 0.5% |
| Total | $303.18 avg | 60,218 | $18.3M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $89.4M | — | Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-14 | $44.6M | — | Filing → |